基于知识图谱的我国药物经济学现状与前沿研究

发布时间：2018-10-12 07:04

【摘要】：我国药物经济学学科在我国不断发展,相关药物经济学评价日益增多。目前,我国尚无系统、完备的评价体系对药物经济学评价进行质量评价,也缺乏权威性的机构进行质量评价。为了正确的比较、评估当前我国药物经济学评价的质量,本研究将运用系统评价的方法对当前我国药物经济学相关文献进行质量评价,质量评价将从研究问题、研究设计、研究方法、成本、健康产出、模型分析以及结果与讨论这几方面进行分析,以此对我国药物经济学现状进行分析。为了厘清药物经济学学科发展的历史脉络,发现药物经济学学科内部的联系,促进药物经济学学科长期有效的发展。本研究基于中文期刊全文数据库(CNKI)、Web of Science数据库检索的相关药物经济学文献数据作为数据来源,运用Citespace5.0.3可视化软件从研究主体、研究热点、研究前沿三方面分别构建国内外药物经济学知识图谱。通过绘制属于药物经济学的知识图谱,揭示药物经济学学科演进规律,预测药物经济学学科的未来前沿走向。通过药物经济学的质量评价发现,当前我国药物经济学评价数量、种类较多,但是评价质量良莠不齐,仍需不断加强。特别表现在研究角度不明确、研究时限不长、健康产出指标单一、不采用贴现以及不进行正确的敏感性分析等方面。通过绘制国内外药物经济学知识图谱发现,国际药物经济学研究较为丰富,国内药物经济学研究还处在起步阶段,所以在图谱的绘制上各有详略。国际药物经济学研究相比较于国内药物经济学研究在研究主体、研究热点方面成果更为丰富,两者在研究前沿方面时间跨度上各有长短。国际药物经济学研究前沿更趋于以真实性、信息、互联网为特点的真实世界研究;国内药物经济学研究前沿则为药物经济学与基本药物目录、医疗保险、决策分析、药品定价相关的应用研究,以及中成药药物经济学研究。
[Abstract]:With the development of pharmacoeconomics in China, the evaluation of pharmacoeconomics is increasing day by day. At present, there is no systematic, complete evaluation system to evaluate the quality of pharmacoeconomics, and there is also a lack of authoritative institutions to evaluate the quality. In order to compare correctly and evaluate the quality of the current pharmacoeconomics evaluation in China, this study will use the method of systematic evaluation to evaluate the quality of the literature related to pharmacoeconomics in China. The research methods, cost, health output, model analysis, results and discussion are analyzed in order to analyze the current situation of pharmacoeconomics in China. In order to clarify the historical context of the development of pharmacoeconomics, the relationship within pharmacoeconomics is found to promote the long-term and effective development of pharmacoeconomics. This study is based on the literature data of pharmacoeconomics retrieved from (CNKI), Web of Science database of Chinese periodical full-text database as a data source, using Citespace5.0.3 visualization software from the main body of research, research focus. The knowledge map of pharmacoeconomics at home and abroad is constructed in three aspects of the research frontier. By drawing the knowledge map of pharmacoeconomics, the evolution law of pharmacoeconomics is revealed, and the future frontier trend of pharmacoeconomics is predicted. Through the quality evaluation of pharmacoeconomics, it is found that there are many kinds of pharmacoeconomics evaluation in our country at present, but the quality of evaluation is mixed, which still needs to be strengthened. Especially in the research angle is not clear, the research time is not long, the health output index is single, does not use the discount and does not carry on the correct sensitivity analysis and so on. Through drawing the knowledge map of pharmacoeconomics at home and abroad, it is found that the international pharmacoeconomics research is relatively rich, and the domestic pharmacoeconomics research is still in its infancy, so there are some details in drawing the map. Compared with domestic pharmacoeconomics research, the international pharmacoeconomics research has more achievements in the research subjects and hot spots, and they have their own time span in the research frontier. The research frontier of international pharmacoeconomics tends to be real world research characterized by truthfulness, information and the Internet, while the frontier of domestic pharmacoeconomics research is pharmacoeconomics and essential drug catalogue, medical insurance, decision analysis. Drug pricing related to the application of research, as well as the economics of proprietary Chinese medicine.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R956

【参考文献】